Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation: a Prospective, Exploratory Study
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2019
Price : $35 *
At a glance
- Drugs Icotinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ICAPE
- Sponsors Betta Pharmaceuticals Co Ltd; Zhejiang Betta Pharma
- 01 Jul 2016 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
- 01 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.
- 12 Mar 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.